Litchfield Hills analyst Theodore O'Neill initiated coverage of Vyome with a Buy rating and $8 price target. The company's drug development operating system repurposes an FDA-approved molecule for a rare orphan indication via topical reformulation, the analyst tells investors in a research note. The firm says this reduces discovery risk, trial size, and timelines while capturing regulatory incentives. VT-1953 delivered statistically significant Phase 2 results in malignant fungating wounds, is funded through mid-2027 interim data, and faces no approved competition, contends Litchfield.
